Author + information
- Received June 24, 2009
- Revision received September 4, 2009
- Accepted October 13, 2009
- Published online January 1, 2010.
- Edward L. Hannan, PhD⁎,⁎ (, )
- Zaza Samadashvili, MD⁎,
- Gary Walford, MD†,
- David R. Holmes Jr, MD‡,
- Alice K. Jacobs, MD§,
- Nicholas J. Stamato, MD∥,
- Ferdinand J. Venditti, MD¶,
- Samin Sharma, MD# and
- Spencer B. King III, MD⁎⁎
- ↵⁎Reprint requests and correspondence:
Dr. Edward L. Hannan, Distinguished Professor and Associate Dean for Research, School of Public Health, State University of New York, University at Albany, One University Place, Rensselaer, New York, 12144-3456
Objectives The purpose of this study was to examine the differences in in-hospital and longer-term mortality for ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease as a function of whether they underwent single-vessel (culprit vessel) percutaneous coronary interventions (PCIs) or multivessel PCI.
Background The optimal treatment of patients with STEMI and multivessel disease is of continuing interest in the era of drug-eluting stents.
Methods STEMI patients with multivessel disease undergoing PCIs in New York between January 1, 2003, and June 30, 2006, were subdivided into those who underwent culprit vessel PCI and those who underwent multivessel PCI during the index procedure, during the index admission, or staged within 60 days of the index admission. Patients were propensity-matched and mortality rates were calculated at 12, 24, and 42 months.
Results A total of 3,521 patients (87.5%) underwent culprit vessel PCI during the index procedure. A total of 259 of them underwent staged PCI during the index admission and 538 patients underwent staged PCI within 60 days of the index procedure. For patients without hemodynamic compromise, culprit vessel PCI during the index procedure was associated with lower in-hospital mortality than multivessel PCI during the index procedure (0.9% vs. 2.4%, p = 0.04). Patients undergoing staged multivessel PCI within 60 days after the index procedure had a significantly lower 12-month mortality rate than patients undergoing culprit vessel PCI only (1.3% vs. 3.3%, p = 0.04).
Conclusions Our findings support the American College of Cardiology/American Heart Association (ACC/AHA) recommendation that culprit vessel PCI be used for STEMI patients with multivessel disease at the time of the index PCI when patients are not hemodynamically compromised. However, staged PCI within 60 days after the index procedure, including during the index admission, is associated with risk-adjusted mortality rates that are comparable with the rate for culprit vessel PCI alone.
- culprit vessel revascularization
- multivessel revascularization
- primary PCI
- ST-segment elevation myocardial infarction
Dr. Sharma has received grant support from Boston Scientific, Inc. (>$10,000), and has served on the Speakers' Bureau for Boston Scientific, Inc. (>$10,000), Abbott Vascular (>$10,000), Lilly (>$10,000), The Medicine Co. (>$10,000), and Datascope (>$10,000). Dr. King has received royalties from Cordis (<$10,000), and served as advisor to Medtronic (<$10,000). Sotirios Tsimikas, MD, served as Guest Editor for this article.
- Received June 24, 2009.
- Revision received September 4, 2009.
- Accepted October 13, 2009.
- American College of Cardiology Foundation